

Jefferies London Healthcare Conference

lan Crosbie, CEO – 16 November 2021

## Innovators in the treatment of diuretic-resistant fluid overload

liver disease 🔵 malignant ascites 🐚 heart failure

### **Disclaimers**

#### **Important Notice**

IMPORTANT: You must read the following before continuing. The following applies to this document, the oral presentation of the information in this document by Sequana Medical NV (the "Company") or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation:

- This presentation has been prepared by the management of the Company. It does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company or any member of its group nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company or any member of its group, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Prospective investors are required to make their own independent investigations and appraisals of the business and financial condition of the Company and the nature of its securities before taking any investment decision with respect to securities of the Company. This presentation is not a prospectus or offering memorandum.
- The information included in this presentation has been provided to you solely for your information and background and is subject to updating, completion, revision and amendment and such information may change materially. No person is under any obligation or undertaking to update or keep current the information contained in this presentation and any opinions expressed in relation thereto are subject to change without notice. No representation or warranty, express or implied, is made as to the fairness, accuracy, reasonableness or completeness of the information contained herein. Neither the Company nor any other person accepts any liability for any loss howsoever arising, directly or indirectly, from this presentation or its contents.
- The presentation also contains information from third parties. Third party industry publications, studies and surveys may also contain that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company reasonably believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company, or any of their respective parent or subsidiary undertakings or affiliates, or any of their respective directors, officers, employees, advisers or agents have independently verified the data contained therein. Thus, while the information from third parties has been accurately reproduced with no omissions that would render it misleading, and the Company believes it to be reliable, the Company cannot guarantee its accuracy or completeness. In addition, certain of the industry and market data contained in this presentation comes from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. While the Company reasonably believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice. Accordingly, undue reliance should not be placed on any of the industry, market or competitive position data contained in this presentation.
- This presentation includes forward-looking statements that reflect the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results, condition, performance, prospects, growth, strategies and the industry in which the Company operates. These forward-looking statements are subject to risks, uncertainties and assumptions and other factors that could cause the Company's actual results, condition, performance, prospects, growth or opportunities, as well as those of the markets it serves or intends to serve, to differ materially from those expressed in, or suggested by, these forward-looking statements. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. The Company cautions you that forward-looking statements are not guarantees of future performance and that its actual results and condition and the development of the industry in which the Company operates may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. In addition, even if the Company's

results, condition, and growth and the development of the industry in which the Company operates are consistent with the forward-looking statements contained in this presentation, those results or developments may not be indicative of results or developments in future periods. The Company and each of its directors, officers and employees expressly disclaim any obligation or undertaking to review, update or release any update of or revisions to any forward-looking statements in this presentation or any change in the Company's expectations or any change in events, conditions or circumstances on which these forward-looking statements are based, except as required by applicable law or regulation.

- This document and any materials distributed in connection with this document are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of, or located in, any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe any such restrictions.
- The Company's securities have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration under the Securities Act or exemption from the registration requirement thereof.
- By attending the meeting where this presentation is presented or by accepting a copy of it, you agree to be bound by the foregoing limitations.

#### **Regulatory disclaimer:**

- The alfapump<sup>®</sup> system has not yet received regulatory approval in the United States and Canada. Any statement in this presentation about safety and efficacy of the alfapump<sup>®</sup> system does not apply to the United States and Canada. In the United States and Canada, the alfapump<sup>®</sup> system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study visit <u>www.poseidonstudy.com</u>.
- DSR<sup>®</sup> therapy is still under development and it should be noted that any statements regarding safety and efficacy
  arise from ongoing pre-clinical and clinical investigations which have yet to be completed. DSR<sup>®</sup> therapy is currently
  not approved for clinical research in the United States or Canada. There is no link between DSR<sup>®</sup> therapy and
  ongoing investigations with the alfapump<sup>®</sup> system in Europe, the United States or Canada.

#### COVID-19 disclaimer:

- Sequana Medical is closely following the evolution of the COVID-19 global health crisis and is in constant dialogue
  with its partners to assess the impact and adapt operations accordingly.
- Sequana Medical has put in place mitigation plans to minimise delays. The impact of increased demands on the healthcare systems, limitations on non-essential hospital visits and procedures, social-distancing and travel restrictions may result in further delays to execution of clinical studies and impact sales.
- Sequana Medical will continue to update the market as needed and whenever possible.

#### Note:

alfapump<sup>®</sup> is a registered trademark. DSR<sup>®</sup> and alfapump DSR<sup>®</sup> are registered trademarks in the Benelux, China, the EU, United Kingdom, and Hong Kong.

## **Treating diuretic-resistant fluid overload**


Multi billion € markets with clear unmet clinical needs

- Fluid overload is a key clinical problem in liver failure, heart failure, renal failure and cancer
- Diuretics are standard of care we are NOT replacing these
- Diuretic-resistance is common and alternatives have significant disadvantages
- We use our **alfa**pump<sup>®</sup> and DSR<sup>®</sup> technologies to develop therapies to deliver:
  - improved clinical outcomes
  - better quality of life for patients
  - cost savings to healthcare systems



## alfapump® platform


Eliminating fluid from the peritoneal cavity – working in partnership with the bladder



Proven capabilities – over 850 systems implanted Strong IP barriers through extensive patent portfolio & know-how


## **Direct Sodium Removal (DSR®) platform**

Eliminating fluid spread across the body – working in partnership with the kidneys



Fundamental patents to reduce fluid overload in heart failure patients granted in the US and Europe

## Focus on two products – € billion opportunities



alfapump DSR®

#### **Congestion due to Heart Failure**

> €5 Bn / year market opportunity in EU & US<sup>(2)</sup>


SAHARA DESERT study ongoing

Partnering after US efficacy study

#### **Built upon proven European clinical & commercial experience**

## **NASH drives US market attractiveness**

Liver cirrhosis is transitioning to a mainstream disease requiring modern treatment options




Notes: current estimated EU Liver market: Data from 1980-2010, death rates between 9-12.4 per 100,000; Mokdad et al., 2014, Management estimates of 7.5% cirrhosis patients that die per year based on experts feedback. forecast US Liver market: Management estimate that is inclusive of estimated growth in prevalence of NASH for the US based on GlobalData Epidemiology Forecast to 2026.

## **alfapump**<sup>®</sup> Proven step change in the treatment of liver refractory ascites and malignant ascites

sequana medical

## **Refractory ascites – key complication of liver cirrhosis**

Fatty liver disease / NASH is driving dramatic growth and change in attitudes to liver cirrhosis patients



Note : Prevalence of NASH in US is expected to increase by 63% between 2015-2030; Estes et al., 2018 Source 1 Management estimate in US based on Estes et al; GlobalData Nash Epidemiology Forecast to 2026; Noureddin et al., 2013 Source 2: Runyon 2009: approximately 50% of cirrhotic patients develop ascites within 10 years of diagnosis of cirrhosis Source 3: Ginès et al., NEJM 2004: refractory ascites occurs in 5-10% patients with ascites Source 4: Presentation of Dr. Rajiv Jalan at EASL in 2018, Large Volume Paracentesis (LVP) treatment cycle for refractory ascites


## **Limitations of existing therapies**

#### Drainage ("Large Volume Paracentesis / LVP")



Painful, Poor Quality of Life, Short Term Benefit

#### **Transjugular Intrahepatic Portosystemic Shunt (TIPS)**



Complications, Contraindications

## alfapump®



#### **Permanent Catheter System**



External Catheter, Risk for Infections / Blockage




**Liver transplantation** 

High Cost, Limited Availability

10

## alfapump® for long-term treatment

Over 850 implants and hundreds of years of patient experience





 $\bigcirc$ 

#### Reduce burden of disease



#### Reduce cost












## **North American Pivotal Study (POSEIDON) underway**

**Pivotal Cohort of up to 50 implanted patients** 



#### **POSEIDON Study Endpoints**

Primary efficacy: 1) 50% reduction in average monthly frequency of Therapeutic Paracentesis ("TP") post-implant vs. pre-implant
 2) 50% of patients achieve a 50% reduction in the requirement for TP post-implant vs. pre-implant
 Primary safety: Rate of alfapump related re-interventions adjudicated by the Clinical Events Committee (CEC)
 Secondary: QoL (SF36, Ascites-Q), nutritional status, health economics, safety (device and/or procedure-related AEs), survival

## **Interim POSEIDON: Positive for primary endpoints**

Data from 26 Roll-In ("training") patients having a similar profile as Pivotal patients

#### **EFFICACY**

- ✓ Over 90% reduction in mean Therapeutic Paracentesis (TP) frequency (primary endpoint >50% reduction)
- ✓ 100% patients with > 50% reduction in mean TP frequency per month (primary endpoint >50% of patients)


#### SAFETY

 $\checkmark$  In line with expectations – 3 composite primary safety events

#### **QUALITY OF LIFE**

✓ Clinically important improvement maintained for up to 12 months post-implantation

## Pursuing North American alfapump® approval






NTAP for breakthrough devices de-risks reimbursement in key Medicare population

PMA: Pre-Market Approval; NTAP: New Technology Add-On Payment

Note: Presented timelines are subject to further developments related to the COVID-19 pandemic

## **US commercialisation through our specialty salesforce**




Initial focus on key transplant centres ~50-person team: 35 sales reps, 10 clinical, 5 corporate

## **alfapump DSR®** Breakthrough approach to persistent congestion in heart failure built on proven alfapump® platform

## **Diuretic-resistant congestion in heart failure**

Clear unmet clinical need and driver of costs for heart failure patients




- 40% of heart failure patients on IV loop diuretics have a poor response<sup>(1)</sup>
- 24% re-admission rate at 30 days<sup>(2)</sup>

Source 1: Testani, Circ Heart Failure, 2014 & 2016; Source 2: Ross et al. (2010); Source 3: Costanzo et al., J. Am. Coll., 2007; Source 4: Kilgore et al. (2017)

## alfapump DSR® leveraging proven alfapump® platform

Fully implanted system for long-term DSR<sup>®</sup> therapy



Sodium-free DSR infusate administered to peritoneal cavity via implanted subcutaneous port

Sodium diffuses into DSR infusate



alfapump pumps sodium-rich DSR infusate into the bladder



Body eliminates excess fluid through osmotic ultrafiltration and urination

Presented as Late-Breaker and Highlight at Heart Failure 2021

## **RED DESERT: repeated dose alfa**pump **DSR® study**

Eight euvolemic heart failure patients on high dose diuretics

#### Highly effective management of fluid and sodium balance

- DSR treatment 3x per week for up to 6 weeks
- · Generally safe and well tolerated; no clinically relevant hyponatremia

#### **Dramatic and long-term improvement in diuretic response**

- Over 150% increase in diuretic response\*\*
- 79% reduction in diuretic dose\*\* 10 months after study completion\*\*\*

#### **Significant improvement in cardio-renal function**


- 30% decrease\* in NT-proBNP\*\* (p<0.001)
- 22% increase\* in eGFR\*\* (p<0.001) / 22% decrease\* in creatinine\*\* (p<0.001)

#### "Simultaneous normalisation of diuretic response and improvement in cardio-renal status is a never before seen treatment effect" – Dr. Testani, Yale

\* Paired statistical analysis of patients with baseline and D42 value (N=7); \*\* mean value \*\*\*median follow-up **NT-proBNP**: N-terminal-pro hormone B-type Natriuretic Peptide (analysed in local lab); **eGFR**: estimated glomerular filtration rate

## **Persistent congestion and Worsening renal function**


Key drivers of mortality in decompensated heart failure



Wattad et al, American Journal of Cardiology, 2015: interaction between worsening renal function and persistent congestion in acute decompensated heart failure (study of 762 patients)

## **SAHARA DESERT: Targeting persistent congestion**

20 decompensated heart failure patients with persistent congestion on high dose diuretics – ongoing



#### **Study Endpoints**

- **Primary:** safety and tolerability of **alfa**pump DSR<sup>®</sup> therapy
- Secondary: feasibility of DSR therapy to restore and maintain euvolemia without additional loop diuretics
- Exploratory: evaluate potential impact of SGLT-2 inhibitors on DSR therapy\*

#### Interim results expected Q4 2021 / Top-line results expected H2 2022

## **Proprietary DSR® Infusate 2.0 drives value model**

- D10% used as initial DSR infusate for fastest proof-of-concept
- We are developing our proprietary next-generation DSR infusate:



Improved therapeutic profile

✓ IP protected

Recurring revenue from high gross margin consumable

Note: This image is intended for illustration purposes only

## **Short-term DSR® – Derisking & extending franchise**

Simplifying regulatory path and preparing market for alfapump DSR® market entry

#### Short-term DSR – "drug only"

- "one off" ~2 weeks intensive DSR treatment
- With peritoneal catheter (no alfapump)

#### Long-term alfapump DSR – "drug / device"


- Intermittent, recurring, intensive DSR treatment
- With **alfa**pump



Tackling residual congestion and restoring diuretic response and cardio-renal status in diuretic-resistant heart failure patients

## **DSR® – Robust development program\***

Step-by-step approach to introduction of breakthrough therapy



Description and timing of these studies are subject to change and/or feedback from applicable regulatory authorities


# Outlook

# Strong near term value drivers with clear long term potential


sequana medical

## **Building on our two proprietary platforms**

Complementary approaches to diuretic-resistant fluid overload



### **Strong outlook for value drivers**



# Contact info

IR@sequanamedical.com
 +32 498 053579

www.sequanamedical.com

sequanamedical